Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Relative Standard Deviation

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    37 result(s) found for: Relative Standard Deviation. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2004-004700-20 Sponsor Protocol Number: 2104-02 Start Date*: 2005-03-11
    Sponsor Name:Epix Pharmaceuticals, Inc.
    Full Title: Phase II Feasibility study of safety and efficacy of Magnetic Resonance Imaging of Thrombi with EP-2104R in the detection in Venous Thromboembolism (VTE)
    Medical condition: Detection of venous thromboembolism
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-004701-23 Sponsor Protocol Number: 2104-03 Start Date*: 2005-03-14
    Sponsor Name:Epix Pharmaceuticals, Inc.
    Full Title: Phase II feasibility study to evaluate the safety and efficacy of EP-2104R for Magnetic Resonance Imaging of thrombi in the arterial vasculature and cardiac chambers
    Medical condition: Detection of thrombi in the arterial vasculature and cardiac chambers
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002520-82 Sponsor Protocol Number: CLO-MEAS Start Date*: 2015-08-27
    Sponsor Name:Prof., dr. med. Anders Fink-Jensen
    Full Title: The significance of deviation in time from the 12-hour standard serum-clozapine monitoring
    Medical condition: Treatment-resistant schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004873 10039642 Schizophrenic disorders LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2005-005594-29 Sponsor Protocol Number: Moli1901-010 Start Date*: 2006-10-31
    Sponsor Name:AOP Orphan Pharmaceuticals AG
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Aerosolized Moli1901 in Adolescents (12 Years of Age or Older) and Adults with Cystic Fibrosis
    Medical condition: Cystic Fibrosis
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) CZ (Prematurely Ended) SK (Completed)
    Trial results: View results
    EudraCT Number: 2015-003079-31 Sponsor Protocol Number: QRK207 Start Date*: 2016-10-20
    Sponsor Name:Quark Pharmaceuticals Inc.
    Full Title: A PHASE 2/3, RANDOMIZED, DOUBLE-MASKED, SHAMCONTROLLED TRIAL OF QPI-1007 DELIVERED BY SINGLE OR MULTI-DOSE INTRAVITREAL INJECTION(S) TO SUBJECTS WITH ACUTE NONARTERITIC ANTERIOR ISCHEMIC OPTIC NEU...
    Medical condition: NAION typically presents as an abrupt, painless monocular vision loss. Visual loss varies widely, ranging from visual field loss only to complete blindness. The neuronal degeneration process in N...
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10068242 Nonarteritic anterior ischaemic optic neuropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-005241-38 Sponsor Protocol Number: LX6171.1-201-AAMI Start Date*: 2007-11-12
    Sponsor Name:Lexicon Pharmaceuticals Incorporated
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Determine Safety and Tolerability of LX6171 Oral Suspension Dosed for 28 Days in Subjects Exhibiting Age Associated Memory Impairment (AAMI) ...
    Medical condition: Age-Associated Memory Impairment (AAMI)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027175 Memory impairment LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2004-002170-34 Sponsor Protocol Number: 2004-002170-34 Start Date*: 2006-03-29
    Sponsor Name:Cambridge University Hospital (Addenbrookes Hospital)
    Full Title: "Ensayo clínico controlado randomizado sobre el tratamiento precoz con insulina en recién nacidos de muy bajo peso"
    Medical condition: Very low birth weight infants requiring intensive care have relative insulin deficiency often leading to hyperglycaemia during the first week of life. There is increasing evidence that the early po...
    Disease:
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-001107-38 Sponsor Protocol Number: SESCHI.26371 Start Date*: 2008-05-26
    Sponsor Name:Cefak KG
    Full Title: Dose finding study to investigate efficacy and tolerability of a 6 month oral treatment with selenium in patients with autoimmune thyroiditis: prospective, controlled parallel group study with Cef...
    Medical condition: Autoimmune thyroiditis (Hashimoto-thyroiditis)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10014698 - Endocrine disorders 10019167 Hashimoto's thyroiditis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-002749-38 Sponsor Protocol Number: BT0800NED001 Start Date*: 2007-07-18
    Sponsor Name:Barrier Therapeutics nv
    Full Title: A randomized, double-blind, placebo-controlled exploratory trial to evaluate a one-week oral treatment with R129160 (60 mg o.d.) in patients with chronic idiopathic urticaria
    Medical condition: Chronic Idiopathic Urticaria
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001443-19 Sponsor Protocol Number: AC-058A200 Start Date*: 2008-11-26
    Sponsor Name:Actelion Pharmaceuticals Ltd
    Full Title: Multicenter, randomized, double-blind, placebo-controlled, Phase IIa study to evaluate the efficacy, safety, and tolerability of ACT-128800, an S1P1 receptor agonist, administered for 6 weeks to su...
    Medical condition: Moderate to severe chronic plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10037153 Psoriasis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) HU (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2020-000546-34 Sponsor Protocol Number: NN8022-4392 Start Date*: 2021-02-10
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effect and safety of liraglutide 3.0 mg on weight management in children with obesity aged 6 to <12 years: 56-week, double-blind, randomised, placebo-controlled trial
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) PT (Trial now transitioned) NO (Not Authorised)
    Trial results: (No results available)
    EudraCT Number: 2018-002474-52 Sponsor Protocol Number: AM-125-CL-18-01 Start Date*: 2019-04-01
    Sponsor Name:Auris Medical AG
    Full Title: Multicenter randomized controlled phase 2 trial to evaluate AM-125 in the treatment of acute peripheral vertigo following neurosurgery (TRAVERS)
    Medical condition: Treatment of acute peripheral vertigo
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004854 10059614 Vestibular vertigo LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) PL (Completed) DE (Completed) GB (GB - no longer in EU/EEA) SK (Completed) IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2012-000216-28 Sponsor Protocol Number: KIMIII Start Date*: 2013-01-14
    Sponsor Name:Medizinische Universität Wien, Universitätsklinik für Innere Medizin III
    Full Title: Treat-To-Target Trial of Continuous Subcutaneous , sensor-augmented insulin-pump therapy in new-onset diabetes after transplantation (SAPT-NODAT): Efficacy and Safety of an Intensive Insulin Protoc...
    Medical condition: New onset diabetes after organ-transplantation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2022-001906-24 Sponsor Protocol Number: LAMA/2021/1 Start Date*: 2022-11-14
    Sponsor Name:Medical University in Lodz
    Full Title: LAMAinDiab - lisdexamphetamine vs methylphenidate for pediatric patients with ADHD and type 1 diabetes - a randomized crossover clinical trial .
    Medical condition: Patients with ADHD and type I diabetes.
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004873 10068453 ADHD, predominantly inattentive type LLT
    21.1 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-000188-33 Sponsor Protocol Number: MK-8616-146 Start Date*: 2017-10-27
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 4 Randomized, Active-Comparator Controlled Trial to Study the Efficacy and Safety of Sugammadex (MK-8616) for the Reversal of Neuromuscular Blockade Induced by Either Rocuronium Bromide or ...
    Medical condition: Reversal of neuromuscular blockade
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10018061 General anesthesia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) BE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-001616-33 Sponsor Protocol Number: MEM-MD-91 Start Date*: 2012-11-14
    Sponsor Name:Forest Research Institute, Inc.
    Full Title: An Open-Label Study Of The Safety And Tolerability Of Memantine In Pediatric Patients With Autism, Asperger’s Disorder, Or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
    Medical condition: Autism or Asperger’s Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10003484 Asperger's disorder PT
    14.1 10029205 - Nervous system disorders 10008520 Childhood autism LLT
    14.1 10037175 - Psychiatric disorders 10034739 Pervasive developmental disorder NOS LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) BE (Completed) ES (Completed) NL (Ongoing) EE (Completed) IS (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-004175-12 Sponsor Protocol Number: B7931028 Start Date*: 2019-10-01
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, DOSE RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06700841 IN PARTICIPANTS WITH ACTIVE SYSTEMIC LUPUS ERYTH...
    Medical condition: Systemic Lupus Erythematosus (SLE)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) HU (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) RO (Ongoing) BG (Completed) PT (Completed) DE (Completed) PL (Completed) ES (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-001012-23 Sponsor Protocol Number: AUX-TG-222 Start Date*: 2007-04-19
    Sponsor Name:Auxilium UK Limited
    Full Title: A Randomized, Double-Blind, Two-Way Crossover Study to Determine the Bioequivalence of a Single Dose of Testim® 1% With Pentadecalactone 1% Relative to a Single Dose of Testim® 1% With Pentadecalac...
    Medical condition: Subjects will be hypogonadal men with an 0800 hr (±30 minutes) serum testosterone level ≤ 350 ng/dL
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021011 Hypogonadism male LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2014-004525-41 Sponsor Protocol Number: 14VR4 Start Date*: 2015-04-10
    Sponsor Name:Versartis, Inc.
    Full Title: Comparison of Somavaratan (VRS-317), a Long-acting Human Growth Hormone, to Daily rhGH in a Phase 3, Randomized, One-year, Open-label, Multi-center, Non-inferiority Trial in Pre-pubertal Children w...
    Medical condition: Growth hormone deficiency
    Disease: Version SOC Term Classification Code Term Level
    19.0 10014698 - Endocrine disorders 10056438 Growth hormone deficiency PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed) BE (Completed) NL (Ongoing) PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-002059-38 Sponsor Protocol Number: APRIL Start Date*: 2021-02-25
    Sponsor Name:APTATARGETS S.L.
    Full Title: A Double-Blind, Placebo-Controlled, Randomized, Phase Ib/IIa Clinical Study of ApTOLL for the Treatment of Acute Ischemic Stroke
    Medical condition: Acute Ischemic Stroke (AIS)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) PT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 19:56:34 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA